Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 1, 2025 • 1:11 PM ET

Date/Time Source News Release
03/27/2025 04:01 PM EDT Business Wire Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results
03/20/2025 08:00 AM EDT Business Wire Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
02/19/2025 08:00 AM EST Business Wire Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
01/27/2025 07:55 AM EST Business Wire Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer
12/09/2024 08:15 AM EST Business Wire Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC(TM) Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
12/03/2024 08:00 AM EST Business Wire Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
11/26/2024 08:45 AM EST Business Wire Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
11/19/2024 08:00 AM EST Business Wire Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC(TM) Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
11/07/2024 04:05 PM EST Business Wire Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
11/05/2024 08:00 AM EST Business Wire Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
Page

Additional News

As of April 1, 2025 • 1:11 PM ET

Date/Time Source News Release
03/27/2025 08:36 PM EDT SeekingAlpha Lantern Pharma outlines 2025 clinical milestones and key updates on oncology trials
03/27/2025 08:35 PM EDT SeekingAlpha Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript
03/27/2025 04:48 PM EDT SeekingAlpha Lantern Pharma GAAP EPS of -$0.54 misses by $0.03
03/27/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, March 27th, 2025
03/27/2025 05:30 AM EDT US Earnings Reports Expected earnings - Lantern Pharma Inc.
03/17/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, March 17th, 2025
03/17/2025 05:31 AM EDT US Earnings Reports Expected earnings - Lantern Pharma Inc.
01/06/2025 11:14 AM EST InvestorBrandNetwork Lantern Pharma Inc. (NASDAQ: LTRN) Highlighted for Surprising Price Action
12/18/2024 08:30 AM EST InvestorBrandNetwork InvestorNewsBreaks - Lantern Pharma Inc. (LTRN) Expands HARMONIC(TM) Trial to Asia with First Patient Dosed in Taiwan
11/27/2024 04:31 AM EST US Earnings Reports Expected earnings - Lantern Pharma Inc.
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.